Svennilson Peter is an investment fund managing more than $1.23 billion ran by Peter Svennilson. There are currently 7 companies in Mr. Svennilson’s portfolio. The largest investments include NGM Biopharmaceuticals and Revolution Medicines, together worth $564 million.
As of 28th October 2020, Svennilson Peter’s top holding is 18,017,932 shares of NGM Biopharmaceuticals currently worth over $287 million and making up 23.4% of the portfolio value.
Relative to the number of outstanding shares of NGM Biopharmaceuticals, Svennilson Peter owns less than 0.3% of the company.
In addition, the fund holds 7,977,384 shares of Revolution Medicines worth $278 million, whose value grew 6.5% in the past six months.
The third-largest holding is Nurix Therapeutics worth $236 million and the next is RAPT Therapeutics worth $181 million, with 5,630,497 shares owned.
Currently, Svennilson Peter's portfolio is worth at least $1.23 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Svennilson Peter office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Peter Svennilson serves as the Managing Partner of The Column Group GP, LP and affiliates at Svennilson Peter.
In the most recent 13F filing, Svennilson Peter revealed that it had opened a new position in
Nurix Therapeutics and bought 6,755,881 shares worth $236 million.
This means they effectively own 0.2% of the company.
Nurix Therapeutics makes up
21.4%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in NGM Biopharmaceuticals by buying
310,954 additional shares.
This makes their stake in NGM Biopharmaceuticals total 18,017,932 shares worth $287 million.
NGM Biopharmaceuticals soared 48.5% in the past year.
On the other hand, there are companies that Svennilson Peter is getting rid of from its portfolio.
Svennilson Peter closed its position in Arcus Biosciences on 4th November 2020.
It sold the previously owned 1,767,676 shares for $43.7 million.
Peter Svennilson also disclosed a decreased stake in RAPT Therapeutics by 0.2%.
This leaves the value of the investment at $181 million and 5,630,497 shares.
The two most similar investment funds to Svennilson Peter are Sirios Capital Management L P and Rheos Capital Works. They manage $1.23 billion and $1.22 billion respectively.
Svennilson Peter’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 90.0% of
the total portfolio value.
The fund focuses on investments in the United States as
85.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $976 million.
These positions were updated on November 4th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| NGM Biopharmaceuticals, Inc. |
1.76%
18,017,932
|
$286,665,000 | 23.39% |
| Revolution Medicines, Inc. |
No change
7,977,384
|
$277,613,000 | 22.65% |
| Nurix Therapeutics, Inc. |
Opened
6,755,881
|
$235,848,000 | 19.24% |
| RAPT Therapeutics, Inc. |
16.92%
5,630,497
|
$181,302,000 | 14.79% |
| Constellation Pharmceticls I |
No change
6,051,376
|
$122,601,000 | 10.00% |
| Oric Pharmaceuticals, Inc. |
No change
4,768,181
|
$119,252,000 | 9.73% |
| Arcus Biosciences, Inc. |
Closed
1,767,676
|
$43,732,000 | |
| Gritstone Oncology, Inc. |
48.88%
869,493
|
$2,304,000 | 0.19% |
| No transactions found | |||
| Showing first 500 out of 8 holdings | |||